Keywords: Abbott Labs, Humira, Crohn's disease, European Commission

Abbott's Humira cleared for Crohn's disease in EU

Article | 31 August 2012

The European Commission has approved US health care major Abbott Laboratories’ (NYSE: ABT) blockbuster rheumatoid arthritis drug Humira (adalimumab) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Abbott Laboratories

Go to company listing

Related Drugs

Humira

Go to drug listing